Skip to content
HowShorted

Atara Biotherapeutics, Inc. short interest in 2019

In 2019, Atara Biotherapeutics, Inc.'s disclosed short interest ran from 14.04% of shares outstanding on 15 Jan 2019 to 18.03% on 31 Dec 2019, a change of +3.99 percentage points. The year's high was 20.28% on 15 Jul 2019 and its low 14.04% on 15 Jan 2019, averaging 17.05% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 26.20 days on 15 Feb 2019. Full history: Atara Biotherapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Atara Biotherapeutics, Inc. in 2019

2019 in figures

Start of year
14.04% (15 Jan 2019)
End of year
18.03% (31 Dec 2019)
Change
+3.99 pp
High
20.28% (15 Jul 2019)
Low
14.04% (15 Jan 2019)
Average
17.05%
Highest days to cover
26.20 (15 Feb 2019)
SEC filings marked
9

Every report in 2019

Atara Biotherapeutics, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201914.04%7.83
31 Jan 201914.09%14.55
15 Feb 201915.93%26.20
28 Feb 201916.85%15.0610-K filed, results (8-K)
15 Mar 201917.24%18.02
29 Mar 201915.67%19.24
15 Apr 201915.18%16.29
30 Apr 201914.97%13.61
15 May 201916.90%6.8410-Q filed, results (8-K)
31 May 201917.23%13.11
14 Jun 201917.98%13.11
28 Jun 201917.15%8.41
15 Jul 201920.28%12.77
31 Jul 201915.10%7.81results (8-K)
15 Aug 201915.94%9.1610-Q filed, results (8-K)
30 Aug 201916.57%16.68
13 Sep 201915.81%10.69
30 Sep 201918.76%10.43
15 Oct 201920.07%15.65
31 Oct 201920.11%17.99
15 Nov 201918.33%17.1110-Q filed, results (8-K)
29 Nov 201919.27%17.45
13 Dec 201917.67%15.40
31 Dec 201918.03%13.92

See also: Atara Biotherapeutics, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.